Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099084 · ClinicalTrials.gov registry record · Phase 4
Short Bowel Syndrome and Teduglutide Versus Placebo
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT02099084: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT02099084 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02099084, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
This research study was done to see what the effects are of Teduglutide on people with short bowel syndrome (SBS). Teduglutide is a synthetic medication administered as an injection, which has shown to increase intestinal blood flow, inhibit gastric secretion, increase growth of intestinal cells and increase absorption of nutrients. Teduglutide has demonstrated to decrease Total Parenteral Nutrition (TPN) requirements by 20%. Teduglutide is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. The primary hypotheses for this study were 1) that Teduglutide significantly increases the gastric emptying half time of solids when compared to placebo. 2) Teduglutide will significantly decrease the intestinal permeability and urinary excretion of lactulose when compared to placebo.
Interventions
- DRUG Placebo
- DRUG Teduglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099084
The ClinicalTrials.gov registry entry for NCT02099084 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02099084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02099084 about?
NCT02099084 is a clinical study titled "Short Bowel Syndrome and Teduglutide Versus Placebo". This research study was done to see what the effects are of Teduglutide on people with short bowel syndrome (SBS). Teduglutide is a synthetic medication administered as an injection, which has shown to increase intestinal blood flow, inhibit gastric secretion, increase growth of intestinal cells and...
What is the current status of trial NCT02099084?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2014-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02099084?
The interventions under investigation include: Placebo (DRUG), Teduglutide (DRUG).
Who is sponsoring clinical trial NCT02099084?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.